Optimi Health Corp.·CSE: OPTI·OTCQX: OPTHF
Princeton, British Columbia
GMP manufacturing

What 'pharmaceutical-grade' actually means.

From research-grade to GMP-certified: why controlled-substance drug manufacture is a different category of work — and why commercial access programs require it.

01The processFive stages, one batch record
Step 01

Sterile cultivation

Proprietary mushroom strains are grown on sterilized substrate in Class-B cleanroom conditions. Genetic consistency drives alkaloid yield.

Step 02

Harvest & extraction

Fruiting bodies are harvested at peak alkaloid content, dried under controlled humidity, and extracted using validated solvents with food-grade GMP solvents and a documented COA at each stage.

Step 03

Analytical QC

HPLC-MS confirms identity and potency of psilocybin and related alkaloids. USP-grade impurity panels screen heavy metals, pesticides, and residual solvents.

Step 04

Encapsulation

Dose-titrated capsules are filled on dedicated equipment under full production-batch records. Content uniformity is verified to pharmacopoeial standards.

Step 05

QP release & distribution

A qualified person signs batch release per Health Canada DEL requirements. Shipment occurs under chain-of-custody controls direct to licensed access-program partners.

02Research grade vs GMP
Research grade
  • Single-batch characterization acceptable
  • Impurity specs set by lab-to-lab practice
  • Paper trail ends at the researcher
  • No obligation to a regulator beyond the IRB
GMP-certified
  • Every batch follows validated production procedures
  • Pharmacopoeial impurity panels (USP/EP equivalents)
  • Complete batch records, audited quarterly
  • Regulator-facing QP release; Dealer's Licence conditions
03Princeton facility
20,000
Sq ft GMP footprint
Two adjacent Princeton facilities for commercial-scale cultivation, manufacturing, and QC.
2024
DEL granted
Health Canada Drug Establishment Licence (June 3, 2024) for the manufacture and sale of MDMA + psilocybin capsules.
2026
First commercial MDMA export
1,000 60 mg MDMA capsules shipped to Australia under the TGA Authorised Prescriber Scheme (Feb 9, 2026).